{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:15:47Z","timestamp":1791821747749,"version":"4.3.4"},"reference-count":22,"publisher":"Elsevier BV","issue":"47","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,10,17]],"date-time":"2019-10-17T00:00:00Z","timestamp":1571270400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000161","name":"National Institute of Standards and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000161","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.vaccine.2019.07.003","type":"journal-article","created":{"date-parts":[[2019,7,6]],"date-time":"2019-07-06T16:05:54Z","timestamp":1562429154000},"page":"6996-7002","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":73,"title":["Development of suspension adapted Vero cell culture process technology for production of viral vaccines"],"prefix":"10.1016","volume":"37","author":[{"given":"Chun Fang","family":"Shen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Guilbault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuling","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Mehdy","family":"Elahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Ansorge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9110-8815","authenticated-orcid":false,"given":"Amine","family":"Kamen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9nald","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2019.07.003_b0005","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/1472-6750-11-102","article-title":"Authentication of African green monkey cell lines using human short tandem repeat mark","volume":"11","author":"Almeida","year":"2011","journal-title":"BMC Biotechnol"},{"issue":"9767","key":"10.1016\/j.vaccine.2019.07.003_b0010","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/S0140-6736(10)62228-3","article-title":"Efficacy, safety, and immunogenicity of a Vero-cell-culture-derived trivalent influenza vaccine: a multicentre, double-blind, randomised, placebo-controlled trial","volume":"377","author":"Barrett","year":"2011","journal-title":"The Lancet"},{"key":"10.1016\/j.vaccine.2019.07.003_b0015","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/1472-6750-11-81","article-title":"Serum-free microcarrier based production of replication deficient influenza vaccine candidate virus lacking NS1 using Vero cells","volume":"11","author":"Chen","year":"2011","journal-title":"BMC Biotechnol"},{"key":"10.1016\/j.vaccine.2019.07.003_b0020","unstructured":"Delagrave D, Oubelaid R, Hamberger J. Compositions and Methods for the Production of Alpha-Herpesviruses. United States Patent 8,877,492 B2; 2014."},{"key":"10.1016\/j.vaccine.2019.07.003_b0025","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jbiotec.2018.11.023","article-title":"Optimization of Production of Vesicular Stomatitis Virus (VSV) in suspension serum-free culture medium at high cell density","volume":"289","author":"Elahi1","year":"2019","journal-title":"J Biotechnol"},{"key":"10.1016\/j.vaccine.2019.07.003_b0030","unstructured":"FDA. Points to consider in the characterization of cell lines used for the production of biologics; 1993. <https:\/\/www.fda.gov\/media\/76255\/download> [accessed 28.06.2019]."},{"key":"10.1016\/j.vaccine.2019.07.003_b0035","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1002\/biot.201400388","article-title":"Designing cell lines for viral vaccine production: Where do we stand?","volume":"10","author":"Genzel","year":"2015","journal-title":"Biotechnol J"},{"key":"10.1016\/j.vaccine.2019.07.003_b0040","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1007\/BF01863914","article-title":"Beitrag zur Kollektiven Behandlung Pharmakologischer Reihenversuche","volume":"162","author":"Kaerber","year":"1931","journal-title":"Arch Exp Path Pharmacol"},{"key":"10.1016\/j.vaccine.2019.07.003_b0045","doi-asserted-by":"crossref","unstructured":"Kolell K, Padilla-Zamudio J, Schuchhardt B, Gilliland S, McNorton S, Dalton B, et al. Virus production in Vero cells using a serum-free medium. In: Smith R, editors. Cell technology for cell products. Dordrecht: Springer; 2007. p. 583\u20135.","DOI":"10.1007\/978-1-4020-5476-1_102"},{"key":"10.1016\/j.vaccine.2019.07.003_b0050","doi-asserted-by":"crossref","unstructured":"Knezevic I, Stacey G, Petricciani J, Sheets R. Substrates W. Evaluation of cell substrates for the production of biologicals: revision of WHO recommendations. Report of the WHO Study Group on Cell Substrates for the Production of Biologicals, 22\u201323 April 2009, Bethesda, USA. Biologicals 2010;38:162\u20139.","DOI":"10.1016\/j.biologicals.2009.08.019"},{"key":"10.1016\/j.vaccine.2019.07.003_b0055","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.vaccine.2006.06.083","article-title":"High immunogenic enterovirus 71 strain and its production using serum-free microcarrier Vero cell culture","volume":"25","author":"Liu","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.07.003_b0060","series-title":"Proceedings of vaccine technology VII conference, June 17-22, Mont Tremblant, Quebec, Canada","article-title":"Media formulation to support the growth of Vero cells in suspension.","author":"Logan","year":"2018"},{"issue":"3","key":"10.1016\/j.vaccine.2019.07.003_b0065","first-page":"26","article-title":"Culturing a duck es-derived cell line in single-use bioreactors: a rapid, efficient, and cost-effective vaccine manufacturing system based on suspension culture.","volume":"13","author":"Madeline","year":"2015","journal-title":"Bioprocess Int"},{"key":"10.1016\/j.vaccine.2019.07.003_b0070","unstructured":"Morrow KJ, Sha M. Vero Cell-based Vaccine Production: Rabies and Influenza Cell lines, Media and Bioreactor Options. Review Article. 2013. <https:\/\/online-shop.eppendorf.us\/US-en\/eshopdownload\/downloadbykey\/93796_186> [accessed 29.11.2018]."},{"key":"10.1016\/j.vaccine.2019.07.003_b0075","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1242\/jcs.81.1.65","article-title":"Optimization of environment for high density Vero cell culture: effect of dissolved oxygen and nutrient supply on cell growth and changes in metabolites","volume":"81","author":"Nahapetian","year":"1986","journal-title":"J Cell Sci"},{"key":"10.1016\/j.vaccine.2019.07.003_b0080","doi-asserted-by":"crossref","first-page":"5693","DOI":"10.1016\/j.vaccine.2013.09.051","article-title":"Comparison of influenza virus yields and apoptosis-induction in an adherent and a suspension MDCK cell line","volume":"31","author":"Peschel","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.07.003_b0085","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1016\/j.vaccine.2007.01.086","article-title":"A microcarrier cell culture process for propagating rabies virus in Vero cells grown in a stirred bioreactor under fully animal component free conditions","volume":"25","author":"Rourou","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.07.003_b0090","series-title":"Proceedings of vaccine technology VII conference, June 17-22, 2018, Mont Tremblant, Quebec, Canada","article-title":"Adaptation of Vero cells to suspension culture and rabies virus production on different serum free media.","author":"Rourou","year":"2018"},{"key":"10.1016\/j.vaccine.2019.07.003_b0095","doi-asserted-by":"crossref","first-page":"6420","DOI":"10.1016\/j.vaccine.2009.06.023","article-title":"Production of yellow fever virus in microcarrier-based Vero cell cultures","volume":"27","author":"Souza","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.07.003_b0100","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S1535-6108(03)00241-1","article-title":"VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents","volume":"4","author":"Stojdl","year":"2003","journal-title":"Cancer Cell"},{"key":"10.1016\/j.vaccine.2019.07.003_b0105","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1016\/j.vaccine.2014.02.022","article-title":"Improved poliovirus d-antigen yields by application of different Vero cell cultivation methods","volume":"32","author":"Thomassen","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.07.003_b0110","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13568-019-0794-5","article-title":"Large-scale microcarrier culture of HEK293T cells and Vero cells in single-use bioreactors","volume":"9","author":"Yang","year":"2019","journal-title":"AMB Exp"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19308813?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19308813?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:35:45Z","timestamp":1759401345000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19308813"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":22,"journal-issue":{"issue":"47","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S0264410X19308813"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.07.003","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of suspension adapted Vero cell culture process technology for production of viral vaccines","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2019 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}